Fluphenazine versus low-potency first generation antipsychotic drugs for schizophrenia

Tardy, Magdolna; Leucht, Stefan; Potapov, Andrey; Engel, Rolf R.; Huhn, Maximilian; Kissling, Werner

doi:10.1002/14651858.cd009230

Cited by 7 publications

(2 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…35 Furthermore, because these medications act on the central nervous system, they can cause alterations in saliva by means of indirect actions on the salivary glands. Antipsychotics [36][37][38] , antihistamines, 39 drugs for overactive bladder, 40,41 and anticholinergic bronchodilators 42 also show anticholinergic activity, causing salivary hypofunction.…”

Section: Drugsmentioning

confidence: 99%

Salivary hypofunction: An update on aetiology, diagnosis and therapeutics

Saleh

Figueiredo

Cherubini

et al. 2015

Archives of Oral Biology

198

166

View full text Add to dashboard Cite

Section: Drugsmentioning

confidence: 99%

Salivary hypofunction: An update on aetiology, diagnosis and therapeutics

Saleh

Figueiredo

Cherubini

et al. 2015

Archives of Oral Biology

198

166

View full text Add to dashboard Cite

“…In this study, we focused on two FDA-approved drugs, Fluphenazine (FP) and Trifluoperazine (TFP), and evaluated their roles in tumor-bone interactions. These two agents are modulators of dopaminergic signaling and currently used as antipsychotic medications (10,11). The dopamine system is involved in many neurological functions (12), but it is also important in other tissues, such as the cardiovascular and skeletal systems (13,14).…”

Section: Introductionmentioning

confidence: 99%

Osteocyte-Driven Downregulation of Snail Restrains Effects of Drd2 Inhibitors on Mammary Tumor Cells

et al. 2018

View full text Add to dashboard Cite

While bone is a frequent target of breast cancer-associated metastasis, little is known about the effects of tumor-bone interactions on the efficacy of tumor-suppressing agents. Here we examined the effect of two FDA-approved dopamine modulators, fluphenazine and trifluoperazine, on mammary tumor cells, osteoclasts, osteoblasts, and osteocytes. These agents suppressed proliferation and migration of mammary tumor cells chiefly by antagonizing dopamine receptor D2 and reduced bone resorption by downregulating nuclear factor of activated T cells, cytoplasmic 1 (Nfatc1). Three-dimensional spheroid formation assays revealed that tumor cells have high affinity to osteocytes and type I collagen, and interactions with osteocytes as well as administration of fluphenazine and trifluoperazine downregulated Snail and suppressed migratory behaviors. Unlike the inhibitory action of fluphenazine and trifluoperazine on tumor growth, tumor-osteocyte interactions stimulated tumor proliferation by upregulating NFκB and Akt. In the bone microenvironment, osteocytes downregulated Snail and acted as an attractant as well as a stimulant to mammary tumor cells. These results demonstrate that tumor-osteocyte interactions strengthen dopamine receptor-mediated suppression of tumor migration but weaken its inhibition of tumor proliferation in the osteocyte-rich bone microenvironment. These findings provide novel insight into the cellular cross-talk in the bone microevironment and the effects of dopamine modulators on mammary tumor cells and osteocytes. .

show abstract